CN101519451A - Recombinant human cytotoxic T lymphocyte associate antigen-4 fusion protein gene (sCTLA4-Ig) and pharmaceutical composition thereof - Google Patents

Recombinant human cytotoxic T lymphocyte associate antigen-4 fusion protein gene (sCTLA4-Ig) and pharmaceutical composition thereof Download PDF

Info

Publication number
CN101519451A
CN101519451A CN200910130178A CN200910130178A CN101519451A CN 101519451 A CN101519451 A CN 101519451A CN 200910130178 A CN200910130178 A CN 200910130178A CN 200910130178 A CN200910130178 A CN 200910130178A CN 101519451 A CN101519451 A CN 101519451A
Authority
CN
China
Prior art keywords
pharmaceutical composition
sctla4
fusion protein
sctla
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN200910130178A
Other languages
Chinese (zh)
Other versions
CN101519451B (en
Inventor
侯盛
陈静
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Three country Kin Pharmaceutical (Shanghai) Limited by Share Ltd
Original Assignee
ZHONGXIN GUOJIAN PHARMACEUTICAL CO Ltd SHANGHAI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZHONGXIN GUOJIAN PHARMACEUTICAL CO Ltd SHANGHAI filed Critical ZHONGXIN GUOJIAN PHARMACEUTICAL CO Ltd SHANGHAI
Priority to CN2009101301787A priority Critical patent/CN101519451B/en
Publication of CN101519451A publication Critical patent/CN101519451A/en
Application granted granted Critical
Publication of CN101519451B publication Critical patent/CN101519451B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Abstract

The invention relates to the field of biological pharmacy and discloses a recombinant human cytotoxic T lymphocyte associate antigen-4 fusion protein gene (sCTLA4-Ig) which has high quantificational expression in cells of mammal such as CHO, and the like. The invention also discloses a specific immunosuppressor pharmaceutical composition which contains the active ingredients of extracellular domain of the sCTLA4 and the constant domain of immunoglobulin. The pharmaceutical composition can be combined with CTLA4 ligand on the surface of the antigen presenting cell in the body so as to prevent the combination of B7-1 and/or B7-2 and the CD28 and/or the CTLA4 acceptor on the surface of the T cell, thereby playing the role of inhibiting the organism immunological reaction.

Description

Recombination human sCTLA 4-Ig fusion protein gene and pharmaceutical composition thereof
The application is to be on April 5th, 2005 applying date, and application number is 200510024872.2, and denomination of invention is divided an application for China of " recombination human sCTLA 4-Ig fusion protein gene and pharmaceutical composition thereof " application.
Technical field
The invention belongs to field of biological pharmacy, relate to a kind of antigen-4 fusion protein gene of cytolytic T lymphocyte antigen 4, more particularly, the present invention relates to a kind of recombination human sCTLA 4-Ig fusion protein gene and pharmaceutical composition thereof.
Background technology
Being cytolytic T lymphocyte antigen 4 (Cytotoxic T Lymphocyte associate Antigen-4, CTLA-4 claims CD152 again), is one of significant molecule that is expressed on the activating T cell surface.Studies show that this composition is a negative regulatory factor of keeping T cell stability in the body, have the value-added function that suppresses activation T-cell, constituted a pair of crucial immune-regulating factor with CD28.At present, it is used as the immunosuppression acceptor and has carried out extensive studies, might use as the preparation that suppresses immunological rejection clinically.
T-cell, antigen presenting cell surface participate in producing altogether, and the molecule of hormesis is referred to as costimulatory molecules.Generally acknowledge that at present most important stimulation channels altogether is that B7-CD28 stimulates path altogether.B7 is positioned at antigen presenting cell, combines with the CD28 molecule of T cell surface and can produce common stimulation.Behind t cell activation, its cell surface can occur another can with B7 cell bonded molecule CTLA4.The avidity of CTLA4 and B7 is very high, this molecule with can induce the accent of B7 cell to die after the B7 cell combines.Therefore think that at present it has down regulation to t cell activation, the balance of immunological status plays an important role in the human body for keeping.CTLA4 can also combine with CD80 and CD86, and their avidity is than the obvious height of CD28, and its function is opposite with CD28, and the T cell is had down regulation.
CTLA-4 is a kind of polarity transmembrane protein.The segmental coding region of Fc of outer soluble fractions of this proteic film and antibody molecule is merged the fusion gene sCTLA4-Ig of formation, insert appropriate carriers, can obtain a kind of natural non-existent fusion rotein after importing suitable cell, its existing cell surface receptor is expected original part bonded ability, the same solubility of antibody molecule is arranged again, transformation period and antibody molecule are approaching, keep the active time long.The protein molecular that utilizes human source gene to obtain can not cause immune response in vivo.Be produced out and be successfully used to clinical at present by multiple similar soluble fusion protein matter.The soluble receptors of CTLA4 can combine with the B7 molecule competitively, and its avidity to B7 is far longer than CD28, therefore can suppress the B7-CD28 passage significantly.
CD80 (B7-1) that sCTLA4-Ig and APC go up to express and the avidity of CD86 (B7-2) are higher than the CD28 that expresses on the T cell and the avidity of B7-1 and B7-2.The effect of sCTLA4-Ig is the T cell co-stimulatory effect that suppresses the CD28 mediation.The CD40/CD40L approach is that another group is attacked stimulation molecule, can stimulate T and B cell to transform simultaneously.As seal the CD40/CD40L approach, can prolong the allograft survival of mouse and primates.If associating sCTLA4-Ig and anti-CD 40 L monoclonal antibody seal these two kinds and are total to the hormesis approach with the significant prolongation graft survival.In view of the vital role of T cell in transplant rejection, present clinical use and most immunosuppressor of developing all act on the T cell.
Summary of the invention
Technical problem to be solved by this invention is to provide a kind of recombination human sCTLA 4-Ig fusion protein gene, and it has the described gene order of SEQ ID NO:1.
Technical problem to be solved by this invention also is to provide a kind of recombination human sCTLA 4-Ig fusion protein pharmaceutical composition, comprises sCTLA4-Ig fusion rotein, trehalose and phosphate buffered saline buffer in the described pharmaceutical composition.
More particularly, described recombination human sCTLA 4-Ig fusion protein pharmaceutical composition contains sCTLA4-Ig fusion rotein 10-30mg/ml, contains trehalose 20-50mg/ml, is dissolved in the phosphate buffered saline buffer of 100mM.Such as, wherein can contain CTLA4-Ig fusion rotein 20mg/ml, contain trehalose 40mg/ml, be dissolved in the phosphate buffered saline buffer of 100mM.
More particularly, when the pharmaceutical composition of the described recombination human sCTLA 4-Ig fusion protein of preparation, the pharmaceutical composition of liquid state can be made freeze-dried preparation, resuspended with distilled water when using.
More particularly, described recombination human sCTLA 4-Ig fusion protein pharmaceutical composition can be taked intramuscular administration, intravenous administration, subcutaneous administration or intradermal administration.
In the present invention, " pharmaceutical composition of the present invention " refers to contain the composition of sCTLA4-Ig fusion rotein and pharmaceutically acceptable carrier, can play the effect that suppresses organism immune response.
In the present invention, " (s) CTLA4-Ig fusion rotein " refers to merge formed fusion rotein by people CTLA-4 soluble part (sCTLA-4) and people Ig antibody Fc fragment.
Trehalose (α-D-glucopyranosyl-(glycopyranoside)) is naturally occurring non-reduced type disaccharides.The form of trehalose comprises the trehalose dihydrate compound (TD) of crystal type, and non-crystalline type trehalose (AT) also can be the trehalose of anhydrous form, promptly anhydrous armorphous trehalose (AAT) and anhydrous crystal trehalose (ACT).Can use the trehalose of any physical form among the present invention, comprise trehalose anhydrous, partially hydrated, complete hydration.
When using pharmaceutical composition of the present invention, be that safe and effective amount pharmaceutical composition is used for Mammals, wherein this safe and effective amount is usually at least about 10 μ g sCTLA4-Ig fusion rotein/Kg body weight, and in most of the cases be no more than about 8mg sCTLA4-Ig fusion rotein/Kg body weight, preferably this dosage is about 10 μ g/ kg body weight-Yue 1mg/Kg body weight.Certainly, specifically dosage also should be considered factors such as route of administration, patient health situation, age.
Description of drawings
Fig. 1 has shown the expression vector pMG18-3K that the present invention is used, has indicated element and restriction enzyme site wherein.HCMV pro, human cytomegalovirus M ajor Immediate early promoter; Ck, people κ chain constant region gene; CH, people γ 1 chain constant region gene; PA, the poly-adenosine signal; DHFR, dihydrofolate reductase gene; PUC origin, the plasmid replication initiation site; Amp is an ampicillin resistance gene.
Embodiment
Embodiment 1
The design of recombinant human sCTLA-4 fusion rotein and preparation
1. the design of recombinant human sCTLA-4 gene
In the applicant's existing patent CN01132075.3, the recombinant human sCTLA-4 antigen-4 fusion protein gene structure of the applicant's design is disclosed, in this patent, be starting point to improve proteic expression amount and avidity, the applicant has done further improvement to the gene of sCTLA-4.
Based on above-mentioned existing patent, the present invention is with reference to the rule of some genetic expressions, according to the preferences of existing experience and codon,, designed one section new reorganization sCTLA-4 gene (SEQ ID NO:1) that has the clonal expression operating sequence through hundreds of times design and improvement:
    CAT gctagcATG
GCTATGCACG?TCGCGCAGCC?AGCCGTAGTT?CTCGCGAGGA?GCCGTGGAAT?GGCAAGTATA?60
GTCTGAGACT?AAGCTTCCCC?TGGAAAGGCA?ACGGACGTGC?GAGTCACTGT?CCTACGCCAT?120
GCAGAGAGGC?ACGTCACAGA?GGTGTGAGCC?GCTACGTAGA?ACACCGGAAA?GGACTTCACG?180
TTGCTCGAAG?AGTCGATATG?GACCGGAACA?TCGAGAGGTA?AGCAAGTCAA?GCTGACAATT?240
CATGGTCTCA?GCGCGATGGA?GACCGGTCTG?TAGATGTGGA?ACGTCGACCT?GATGTAGCCT?300
CCACGTTAGT?AGCTCGGAAT?CGGAAAGGGT?AGGCACATAT?ACGTCATAGA?ACCTGATCCC?360
TGGCCTGAAT?CAGAGTTGCT?GCTGTGCATA?CTAGCTGCTG?TAAGATCCGG?CTTCTAATTA?420
TAAAGGTTGC?TACTGACTGC?AGTATCATTC?AGGAATATGC?TTAACAATAG?TAGGCCACTA?480
ACTACTGGCG?TGTAAGTCAA?TATGCCTCCC?ACTGACCCTG?ATTGAGATAA?CCATTTGCAT?540
CCTTAATTAA?TCGGAATGAA?TTGT 564
2.sCTLA-4/Fc the acquisition of fusion gene
Human IgG1 Fc fragments sequence is known (referring to for example Genebank accession number acc82527).With aforesaid sCTLA4 and the plasmid pMG18-3K (Fig. 1 that has total length IgG1 gene, also can be with reference to DEVELOPMENT OF TOOIS FOR ENVIRONMENTAL MONITORING BASED ONINCP-9 PLASMIDS SEQUENCES.A.Greated, R.Krasowiak, M.Titok, C.M.Thomas School of Biological Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK and Faculty of Biology, Dept of Microbiology, BelarusState University Scorina Ay.4, Minsk 220080 Belarus) be template, design corresponding primer, carry out PCR (concrete grammar can referring to the applicant's patent CN01132075.3).Carrying out gel after the acquisition molecular size is about the single band of 1233bp on the agarose gel electrophoresis reclaims.The DNA that obtains is cloned on the pUC18 carrier back transformed into escherichia coli and is carried out blue hickie screening according to ordinary method, cuts by enzyme and identifies and order-checking, confirms the right-on clone of sequence, is sCTLA4/Fc.
Selectable, can also between sCTLA4 and IgG1, add joint sequence, be (Ala 3Ser 2) 5(SEQID NO:2), its gene order is:
5 '-ACCACAACCTCGTCAACCACAACCTCGTCAACCACAACCTCGTCAACCACAACCTC GTCAACCACAACCTCGTCA-3 ' (SEQ ID NO:3) is sCTLA4/ joint/Fc (concrete grammar can referring to the applicant's patent CN01132075.3).
Embodiment 2
The sCTLA-4 Expression of Fusion Protein
1. the structure of integrative gene expression vector
PUC18[sCTLA-4/Fc with aforementioned structure] and pUC18[sCTLA-4/ joint/Fc] correct clone is inoculated in the 20ml liquid LB substratum that contains penbritin, 37 ℃ of overnight incubation, with the Midi plasmid DNA extracting and purifying test kit extracting plasmid DNA of Promega company, each get about 30 micrograms of plasmid DNA.
Use Nhe I and Xho I (Phamarcia) (10U/ μ l) digestion pUC18[sCTLA-4/Fc respectively], pUC18[sCTLA-4/ joint/Fc] and expression plasmid pMSG (Phamarcia).37 ℃ of reactions of endonuclease reaction are spent the night.Enzyme is cut product and carry out isolation identification on 0.8% agarose electrophoresis, is about the fragment of 1500bp with the gel recovery test kit recovery size of Promega company.
Use T4 dna ligase (10U/ μ l) sCTLA-4/Fc or sCTLA-4/ joint/Fc to be connected to the Nhe I and the Xho I site of pMSG carrier respectively.
According to ordinary method (seeing Sambrook etc., 1989) connection gained reorganization pMSG transformed into escherichia coli DH5a bacterial strain, and on the IPTG/X-Gal plate culture medium, carry out blue hickie screening.Respectively get 12 of hickies and be inoculated in and extract plasmid after 37 ℃ of cultivations of LB liquid nutrient medium and carry out enzyme as previously mentioned and cut evaluation, every kind of fusion gene obtains 4 segmental clones of insertion with correct size at least, as candidate clone.
Carry out dna sequencing with two in the above-mentioned candidate clone.According to sequencing result, confirm to insert the in full accord of fragments sequence and design respectively.The correct clone of gained is remembered work: pMSG[sCTLA4/Fc respectively], pMSG[sCTLA4/ joint/Fc].
2.CHO transformation and expression
Get the coli strain that has above-mentioned 2 kinds of reorganization pMSG, be inoculated in the 2xYT liquid nutrient medium that 500ml has added penbritin respectively, 37 ℃, the 260rpm concussion was cultivated 16 hours.With " Ultrapure Plasmid Purification Kit " extracting plasmid DNA of Qiagen company, extractive process is carried out according to the specification sheets that producer provides.
Use the liposome transfection Chinese hamster ovary celI, the transfection reagent box is available from Invitrogene company.Get the pMSG[sCTLA4/ joint/Fc of above-mentioned purifying during transfection respectively], pMSG[sCTLA4/Fc] plasmid 100 micrograms carry out transfection as the DNA sample to Chinese hamster ovary celI, the transfection schedule of operation is carried out according to the specification sheets of producer.
Chinese hamster ovary celI after the transfection is through continuous 3 months methotrexate (MTX) screening, and to 10 μ M, per two weeks increase a concentration to its concentration from 0.05 μ M, and the consumption of each MTX is about previous 2 times, concrete visual cell's growing state and deciding.Cell cultures is carried out according to routine, and substratum is: 15% foetal calf serum (Gibco)+RPM1640/DEME.In 37 ℃, 5%CO 2Cultivate in the incubator.Carry out mono-clonalization according to routine extreme dilution method then.Use the ELISA method and detect its Expression of Fusion Protein amount respectively, obtain pMSG[sCTLA4/ joint/Fc altogether] clone 152, pMSG[sCTLA4/Fc] clone 128.
The conventional cultivation in the DEME substratum, the expression intensity of above-mentioned part clone sCTLA-4 is studied concrete data such as following table with ELISA:
Table 1
Above data declaration, reorganization sCTLA-4 gene of the present invention has significantly improved the Expression of Fusion Protein level, has improved about order of magnitude (10 times) than original level.
Embodiment 3
The sCTLA-4 fusion rotein suppresses the lymphopoiesis Research on ability
With above-mentioned pMSG[sCTLA4/ joint/Fc] and pMSG[sCTLA4/Fc] expression cell line cultivate the back and carry out affinity chromatography with A albumen-Sepharose, acquisition purity reaches the fusion rotein more than 90%.
1. conventional separation of human peripheral blood lymphocyte (PBMC), adjusting cell density is 2 * 10 6Cells/ml, PBMC and equal-volume nutrient solution mix the back with 2 * 10 5Cells/0.2ml/ hole inoculation " U " type 96 well culture plates add not 9 purified fusion proteins with amount, equal-volume corresponding empty carrier transfection supernatant or substratum are set compare, every group 3 multiple hole, 37 ℃, 5%CO 2Cultivate 5d, 16h adds before stopping cultivating 3H-TdR (final concentration 5 μ Ci/ml), collecting cell are dried on 0.45 μ m millipore filtration, and liquid scintillation counter is surveyed the DPM value.
2. the result represents with x ± s, and Microsoft Excel statistics program carries out mean difference significance analysis.
3. at MLR reaction (Linsley P S, Brady W, Urnes M, et al.CTLA-4 is a second receptorfor the B cell activation antigen B7[J] .J Exp Med, 1991,174 (3): 561-569.) in the system, sCTLA4/ joint/Fc, the sCTLA4/Fc or the empty carrier transfection CHO cell supernatant that add 1 microgram, 5 micrograms and 10 microgram Protein A purifying purifying respectively, the result shows, even add the fusion rotein of 1 microgram A protein purification, also can significantly suppress human peripheral MLR, inhibiting rate is 60%~70%; And add the empty carrier transfection CHO cell supernatant of same volume, and then there is not this effect, through one-way analysis of variance, the result has statistical significance.Equally, we also once directly carried out the MLR experiment with the supernatant of unpurified transfectional cell, fail to observe significant inhibitory effect, this may cancel out each other relevant with the hormesis of heterologous protein in the purifying cells transfection supernatant not and the restraining effect of micro-fusion rotein.
Embodiment 4
Preparation of drug combination of the present invention
At first prepare the phosphate buffered saline buffer of 100mM, and regulate the pH value of damping fluid, make it about PH7.0.Add an amount of trehalose in phosphate buffered saline buffer, make it reach 50mg/ml, then add the sCTLA-4 fusion rotein, make it reach 50mg/ml, the medicament of acquisition can directly be applied to Mammals (comprising the people), as by intravenous mode.
In addition, also pharmaceutical composition of the present invention can be made freeze-dried preparation, so that transportation and storage.When needs are used, can pharmaceutical composition of the present invention be carried out with physiology available solvent resuspended, resuspended such as using distilled water to carry out.
<110〉Shanghai CP Guojian Pharmaceutical Co.,Ltd
<120〉recombination human sCTLA 4-Ig fusion protein gene and pharmaceutical composition thereof
<160>3
<210>1
<211>564
<212>DNA
<213〉polynucleotide
<400>1
GCTATGCACG?TCGCGCAGCC?AGCCGTAGTT?CTCGCGAGGA?GCCGTGGAAT?GGCAAGTATA?60
GTCTGAGACT?AAGCTTCCCC?TGGAAAGGCA?ACGGACGTGC?GAGTCACTGT?CCTACGCCAT?120
GCAGAGAGGC?ACGTCACAGA?GGTGTGAGCC?GCTACGTAGA?ACACCGGAAA?GGACTTCACG?180
TTGCTCGAAG?AGTCGATATG?GACCGGAACA?TCGAGAGGTA?AGCAAGTCAA?GCTGACAATT?240
CATGGTCTCA?GCGCGATGGA?GACCGGTCTG?TAGATGTGGA?ACGTCGACCT?GATGTAGCCT?300
CCACGTTAGT?AGCTCGGAAT?CGGAAAGGGT?AGGCACATAT?ACGTCATAGA?ACCTGATCCC?360
TGGCCTGAAT?CAGAGTTGCT?GCTGTGCATA?CTAGCTGCTG?TAAGATCCGG?CTTCTAATTA?420
TAAAGGTTGC?TACTGACTGC?AGTATCATTC?AGGAATATGC?TTAACAATAG?TAGGCCACTA?480
ACTACTGGCG?TGTAAGTCAA?TATGCCTCCC?ACTGACCCTG?ATTGAGATAA?CCATTTGCAT?540
CCTTAATTAA?TCGGAATGAA?TTGT 564
<210>2
<211>25
<212>PRT
<213〉joint peptide
<400>2
Ala?Ala?Ala?Ser?Ser?Ala?Ala?Ala?Ser?Ser?Ala?Ala?Ala?Ser?Ser?Ala
5 10 15
Ala?Ala?Ser?Ser?Ala?Ala?Ala?Ser?Ser
20 25
<210>3
<211>75
<212>DNA
<213〉joint gene
<400>3
ACCACAACCT?CGTCAACCAC?AACCTCGTCA?ACCACAACCT?CGTCAACCAC?AACCTCGTCA?60
ACCACAACCT?CGTCA 75

Claims (5)

1. a recombination human sCTLA 4-Ig fusion protein is characterized in that, described fusion rotein is by the described gene order coding of SEQ ID NO:1.
2. a recombination human sCTLA 4-Ig fusion protein pharmaceutical composition is characterized in that, comprises the described sCTLA4-Ig fusion rotein of claim 1, trehalose and phosphate buffered saline buffer in the described pharmaceutical composition.
3. recombination human sCTLA 4-Ig fusion protein pharmaceutical composition according to claim 2 is characterized in that, wherein contains sCTLA4-Ig fusion rotein 10-30mg/ml, contains trehalose 20-50mg/ml, is dissolved in the phosphate buffered saline buffer of 100mM.
4. recombination human sCTLA 4-Ig fusion protein pharmaceutical composition according to claim 3 is characterized in that, the pharmaceutical composition of liquid state is made freeze-dried preparation, and is resuspended with distilled water when using.
5. any recombination human sCTLA 4-Ig fusion protein pharmaceutical composition in the claim 3-4 is characterized in that, takes any mode in intramuscular administration, intravenous administration, subcutaneous administration, the intradermal administration.
CN2009101301787A 2005-04-05 2005-04-05 Recombinant human cytotoxic T lymphocyte associate antigen-4 fusion protein gene (sCTLA4-Ig) and pharmaceutical composition thereof Active CN101519451B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2009101301787A CN101519451B (en) 2005-04-05 2005-04-05 Recombinant human cytotoxic T lymphocyte associate antigen-4 fusion protein gene (sCTLA4-Ig) and pharmaceutical composition thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2009101301787A CN101519451B (en) 2005-04-05 2005-04-05 Recombinant human cytotoxic T lymphocyte associate antigen-4 fusion protein gene (sCTLA4-Ig) and pharmaceutical composition thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100248722A Division CN100560723C (en) 2005-04-05 2005-04-05 Recombination human sCTLA 4-Ig fusion protein gene and pharmaceutical composition thereof

Publications (2)

Publication Number Publication Date
CN101519451A true CN101519451A (en) 2009-09-02
CN101519451B CN101519451B (en) 2011-05-25

Family

ID=41080272

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009101301787A Active CN101519451B (en) 2005-04-05 2005-04-05 Recombinant human cytotoxic T lymphocyte associate antigen-4 fusion protein gene (sCTLA4-Ig) and pharmaceutical composition thereof

Country Status (1)

Country Link
CN (1) CN101519451B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102382193A (en) * 2011-11-01 2012-03-21 孙嘉琳 Fusion protein capable of inducing and activating cancer-targeted T cells, preparation method and use thereof
CN113372451A (en) * 2010-02-19 2021-09-10 Xencor公司 Novel CTLA4-IG immunoadhesins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100560723C (en) * 2005-04-05 2009-11-18 上海中信国健药业有限公司 Recombination human sCTLA 4-Ig fusion protein gene and pharmaceutical composition thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113372451A (en) * 2010-02-19 2021-09-10 Xencor公司 Novel CTLA4-IG immunoadhesins
CN102382193A (en) * 2011-11-01 2012-03-21 孙嘉琳 Fusion protein capable of inducing and activating cancer-targeted T cells, preparation method and use thereof
CN102382193B (en) * 2011-11-01 2013-08-14 孙嘉琳 Fusion protein capable of inducing and activating cancer-targeted T cells, preparation method and use thereof

Also Published As

Publication number Publication date
CN101519451B (en) 2011-05-25

Similar Documents

Publication Publication Date Title
US20210115107A1 (en) Methods of treatment using ctla4 molecules
ES2302811T3 (en) PROCEDURE TO PROTECT TRANSPLANTS OF ALOGENIC ISLOTES USING MUTING MOLECULES SOBLULES CTLA4.
US20180208639A1 (en) CTLA-4 Variants
ES2225549T3 (en) CTLA4 MODULES MUTAN SOLUBLES AND USES OF THE SAME.
AU2001273174C1 (en) Methods for treating rheumatic diseases using a soluble CTLA4 molecule
US20180256644A1 (en) Tunable variant immunoglobulin superfamily domains and engineered cell therapy
US20020039577A1 (en) Methods for regulating a lymphocyte-mediated immune response by blocking costimulatory signals and blocking LFA-1 mediated adhesion in lymphocytes
CN101198347A (en) Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules
US20040092718A1 (en) Use of a CD28 binding substance for making a pharmaceutical composition
AU2001275411A1 (en) Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking LFA-1 mediated adhesion
Srinivasan et al. Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28
US11672873B1 (en) Anti-B7-H4 antibodies and methods
WO2021247474A1 (en) Sstr-binding chimeric antigen receptors
CN100560723C (en) Recombination human sCTLA 4-Ig fusion protein gene and pharmaceutical composition thereof
EP1702622A1 (en) Soluble BTNL2 protein useful to inhibit inflammatory disorders
CN101519451B (en) Recombinant human cytotoxic T lymphocyte associate antigen-4 fusion protein gene (sCTLA4-Ig) and pharmaceutical composition thereof
US20060233795A1 (en) Methods for selectively modulating a Th2-type response within a population of activated CD4+ T cells
Cho et al. Construction, and in vitro and in vivo analyses of tetravalent immunoadhesins
CN113874389A (en) Interleukin-2 receptor (IL2R) and interleukin-2 (IL2) variants for specific activation of immune effector cells
US20230340068A1 (en) Chimeric antigen receptor (car) with cd28 transmembrane domain
WO2024010955A1 (en) Methods of manufacturing therapeutic cells
US20210379108A1 (en) Car t-cells for the treatment of bone metastatic cancer
BG107210A (en) Soluble ctla4 mutant molecules and uses thereof
NZ542231A (en) Soluble CTLA4 mutant fusion molecules and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: Shanghai city 201203 libing road Pudong New Area Zhangjiang hi tech Park No. 399

Patentee after: Three country Kin Pharmaceutical (Shanghai) Limited by Share Ltd

Address before: Shanghai city 201203 libing road Pudong New Area Zhangjiang hi tech Park No. 399

Patentee before: Shanghai CP Guojian Pharmaceutical Co., Ltd.